BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will host a Research & Development Day to provide updates on the commercial plans for DEXTENZA and a deeper dive into the hydrogel platform and the Company’s pipeline. The event will include presentations by members of Ocular Therapeutix’s senior management team and will include Key Opinion Leaders Tal Raviv, MD, FACS, Founder and Medical Director, Eye Center of New York, Kuldev Singh, MD, Professor of Ophthalmology and Director of the Glaucoma Service, Stanford University Medical Center and Elias Reichel, MD, Professor and Vice Chair, Director, Vitreoretinal Disease and Surgery Service, New England Eye Center, Tufts University School is Medicine.
The presentations will begin at 7:30 a.m. Eastern Time on Thursday, March 28, 2019 in New York, New York.
A live webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.